CCO_Clin_Onc_June_2013_GI_Highlights_Slides课件.pptVIP

下载本文档

1
0
约4.08万字
约 49页
2016-10-26 发布于河南
举报
版权申诉

CCO_Clin_Onc_June_2013_GI_Highlights_Slides课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

* CT, computed tomography; DCR, disease-control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; GIST, gastrointestinal stromal tumor; OS, overall survival; PD, progressive disease; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TTP, time to progression. * GIST, gastrointestinal stromal tumor; PFS, progression-free survival. * DCR, disease-control rate; GIST, gastrointestinal stromal tumor; PFS, progression-free survival; SD, stable disease; TKI, tyrosine kinase inhibitor. * DCR, disease-control rate; GIST, gastrointestinal stromal tumor; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. * * Bev, bevacizumab; CR, complete response; CT, computed tomography; mCRC, metastatic colorectal cancer; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; TTNT, time to new (second-line) treatment; TTP, time to progression; Tx, treatment; WHO PS, World Health Organization performance status. * Bev, bevacizumab; mCRC, metastatic colorectal cancer; TTP, time to progression. * Bev, bevacizumab; mCRC, metastatic colorectal cancer; PFS, progression-free survival. * Bev, bevacizumab; mCRC, metastatic colorectal cancer; OS, overall survival. * Bev, bevacizumab; mCRC, metastatic colorectal cancer; OS, overall survival. * CAPOX, capecitabine, oxaliplatin; IrMdG, irinotecan/modified de Gramont chemotherapy; OS, overall survival; OxMdG, oxaliplatin/modified de Gramont chemotherapy; PFS, progression-free survival; QoL, quality of life; WT, wild type. * mCRC, metastatic colorectal cancer; PFS, progression-free survival; WT, wild type. * ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, irinotecan, 5-fluorouracil, leucovorin; mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure. * Bev, bevacizumab; Cetux, cetuximab; CR, complete response; FOLFIRI, irinot